论文部分内容阅读
目的:观察健择联合顺铂治疗初治进展期食管癌的临床疗效和不良反应。方法:14例初治进展期食管癌患者,采用健择1g/m2d1、8,顺铂40g/m2d8、9,3周为一周期,2周期后评价疗效。结果:14例初治食管癌患者有效率42.9%(6/14),稳定35.7%(5/14)、进展21.4%(3/14)。均能耐受化疗,主要不良反应为骨髓抑制。结论:与传统标准FLP方案相比,健择联合顺铂方案有一定作用,但无明显优势。
Objective: To observe the clinical efficacy and adverse reactions of gemcitabine combined with cisplatin in the treatment of advanced esophageal cancer. Methods: Fourteen patients with newly diagnosed advanced esophageal cancer were treated with gemcitabine 1g / m2d1,8 and cisplatin 40g / m2d8 for 9, and 3 weeks respectively. The therapeutic effect was evaluated after 2 cycles. Results: The effective rate of 14 patients with newly diagnosed esophageal cancer was 42.9% (6/14), stable 35.7% (5/14) and 21.4% (3/14). Can tolerate chemotherapy, the main adverse reaction is myelosuppression. CONCLUSIONS: Compared with the traditional standard FLP regimen, gemcitabine plus cisplatin regimen has a certain effect, but no obvious advantage.